PT1411118E - Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3 - Google Patents

Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3 Download PDF

Info

Publication number: PT1411118E
Authority: PT; Portugal
Prior art keywords: antibody; glypican; cell proliferation; proliferation inhibitors; containing anti
Prior art date: 2001-06-22

Application number

PT02741243T

Other languages

English (en)

Inventor

Hiroyuki Aburatani

Tetsuo Nakamura

Masayuki Tsuchiya

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-22

Filing date

2002-06-21

Publication date

2008-12-09

2002-06-21 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2008-12-09 Publication of PT1411118E publication Critical patent/PT1411118E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Mycology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

PT02741243T 2001-06-22 2002-06-21 Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3 PT1411118E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2001189443		2001-06-22

Publications (1)

Publication Number	Publication Date
PT1411118E true PT1411118E (pt)	2008-12-09

Family

ID=19028362

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT02741243T PT1411118E (pt)	2001-06-22	2002-06-21	Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3
PT100033786T PT2208784E (pt)	2001-06-22	2002-06-21	Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT100033786T PT2208784E (pt)	2001-06-22	2002-06-21	Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3

Country Status (14)

Country	Link
US (3)	US20040236080A1 (pt)
EP (3)	EP2208784B1 (pt)
JP (7)	JP4281869B2 (pt)
KR (3)	KR100877176B1 (pt)
CN (2)	CN101240022B (pt)
AT (2)	ATE407204T1 (pt)
AU (2)	AU2002315857B2 (pt)
CA (1)	CA2451493C (pt)
CY (1)	CY1113854T1 (pt)
DE (2)	DE60237929D1 (pt)
DK (2)	DK2208784T3 (pt)
ES (3)	ES2312586T3 (pt)
PT (2)	PT1411118E (pt)
WO (1)	WO2003000883A1 (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7361336B1 (en) *	1997-09-18	2008-04-22	Ivan Bergstein	Methods of cancer therapy targeted against a cancer stem line
CA2451493C (en)	2001-06-22	2016-08-23	Chugai Seiyaku Kabushiki Kaisha	Cell growth inhibitors containing anti-glypican 3 antibody
WO2004022597A1 (ja) *	2002-09-04	2004-03-18	Chugai Seiyaku Kabushiki Kaisha	Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
CA2482881C (en) *	2002-05-23	2016-11-08	Sunnybrook And Women's College Health Sciences Centre	Diagnosis of hepatocellular carcinoma
EP1671645A4 (en) *	2003-09-04	2007-07-25	Chugai Pharmaceutical Co Ltd	REMEDIES AND MEDIUM FOR DETECTING GALLENGIFT CANCER
PT1674111E (pt) *	2004-07-09	2010-12-15	Chugai Pharmaceutical Co Ltd	Anticorpo anti-glipicano 3
KR20130103580A (ko) *	2004-08-24	2013-09-23	추가이 세이야쿠 가부시키가이샤	항 글리피칸 3 항체를 이용한 어쥬번트 요법
AU2005297772B2 (en) *	2004-10-26	2011-06-23	Chugai Seiyaku Kabushiki Kaisha	Anti-glypican 3 antibody having modified sugar chain
CN101198698B (zh)	2005-03-31	2014-03-19	中外制药株式会社	通过调节多肽缔合制备多肽的方法
EP1901573A1 (en)	2005-08-03	2008-03-19	Matsushita Electric Industrial Co., Ltd.	Base station apparatus, communication terminal apparatus, and multicarrier communication method
US20070087005A1 (en) *	2005-10-14	2007-04-19	Lazar Gregory A	Anti-glypican-3 antibody
US7723043B2 (en)	2006-01-04	2010-05-25	Picobella, Lp	Methods for screening for prostate cancer
JP5144499B2 (ja)	2006-03-31	2013-02-13	中外製薬株式会社	二重特異性抗体を精製するための抗体改変方法
EP3056568B1 (en)	2006-03-31	2021-09-15	Chugai Seiyaku Kabushiki Kaisha	Methods for controlling blood pharmacokinetics of antibodies
ES2562790T3 (es) *	2007-07-17	2016-03-08	E. R. Squibb & Sons, L.L.C.	Anticuerpos monoclonales contra Glipicano-3
RU2526512C2 (ru)	2007-09-26	2014-08-20	Чугаи Сейяку Кабусики Кайся	Модифицированная константная область антитела
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
KR20150126724A (ko)	2007-09-28	2015-11-12	추가이 세이야쿠 가부시키가이샤	혈장 중 반응속도가 개선된 항-글리피칸-3 항체
WO2009072604A1 (ja) *	2007-12-05	2009-06-11	Chugai Seiyaku Kabushiki Kaisha	抗nr10抗体、およびその利用
CL2009000647A1 (es)	2008-04-04	2010-06-04	Chugai Pharmaceutical Co Ltd	Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
CA2721052C (en)	2008-04-11	2023-02-21	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) *	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
EP2409990A4 (en)	2009-03-19	2013-01-23	Chugai Pharmaceutical Co Ltd	VARIANT OF A CONSTANT ANTIBODY REGION
JP5717624B2 (ja)	2009-03-19	2015-05-13	中外製薬株式会社	抗体定常領域改変体
WO2011037158A1 (ja)	2009-09-24	2011-03-31	中外製薬株式会社	抗体定常領域改変体
WO2011108714A1 (ja)	2010-03-04	2011-09-09	中外製薬株式会社	抗体定常領域改変体
KR101962483B1 (ko)	2010-11-17	2019-03-29	추가이 세이야쿠 가부시키가이샤	혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
CN103328632A (zh)	2010-11-30	2013-09-25	中外制药株式会社	与多分子的抗原重复结合的抗原结合分子
EP4279513A3 (en)	2010-11-30	2024-02-28	Chugai Seiyaku Kabushiki Kaisha	Cytotoxicity-inducing therapeutic agent
US20120190049A1 (en) *	2010-12-10	2012-07-26	University Of Washington Through Its Center For Commercialization	Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
WO2012133782A1 (ja)	2011-03-30	2012-10-04	中外製薬株式会社	抗原結合分子の血漿中滞留性と免疫原性を改変する方法
CN112812184A (zh)	2011-02-25	2021-05-18	中外制药株式会社	FcγRIIb特异性Fc抗体
CA2850194C (en)	2011-09-30	2023-03-21	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting elimination of antigens
EP2752200B1 (en)	2011-09-30	2023-11-01	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule inducing immune response to target antigen
TW201817745A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (ja)	2011-09-30	2013-04-04	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
US20150299313A1 (en)	2011-10-05	2015-10-22	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
KR20220136441A (ko)	2012-02-24	2022-10-07	추가이 세이야쿠 가부시키가이샤	ＦｃγＲＩＩＢ를 매개로 항원의 소실을 촉진하는 항원 결합 분자
US20150166654A1 (en)	2012-05-30	2015-06-18	Chugai Seiyaku Kabushiki Kaisha	Target tissue-specific antigen-binding molecule
JP6494507B2 (ja) *	2012-06-01	2019-04-03	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	グリピカン−３に対する高親和性モノクローナル抗体およびその使用
TWI693073B (zh)	2012-12-21	2020-05-11	日商中外製藥股份有限公司	對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP3557260B1 (en)	2012-12-21	2022-05-18	Chugai Seiyaku Kabushiki Kaisha	Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
AU2014325063B2 (en)	2013-09-27	2019-10-31	Chugai Seiyaku Kabushiki Kaisha	Method for producing polypeptide heteromultimer
CN105980557B (zh)	2013-12-04	2020-04-07	中外制药株式会社	抗原结合能力根据化合物的浓度而变化的抗原结合分子及其文库
CN113933504A (zh)	2014-05-08	2022-01-14	中外制药株式会社	对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂
US9926377B2 (en) *	2014-05-22	2018-03-27	Genentech, Inc.	Anti-GPC3 antibodies and immunoconjugates
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
CN104829704B (zh) *	2014-12-15	2016-08-17	河北省科学院生物研究所	一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
IL278014B2 (en)	2014-12-19	2023-10-01	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
AR103162A1 (es)	2014-12-19	2017-04-19	Chugai Pharmaceutical Co Ltd	Anticuerpos anti-c5 y métodos para su uso
KR102435383B1 (ko) *	2015-01-16	2022-08-24	미노믹 인터내셔널 리미티드	글리피칸 에피토프 및 이의 용도
SG10201907215QA (en)	2015-02-05	2019-09-27	Chugai Pharmaceutical Co Ltd	Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
BR112017014067B1 (pt)	2015-02-27	2021-01-12	Chugai Seiyaku Kabushiki Kaisha	usos de um anticorpo receptor de il-6 para no tratamento de doenças relacionadas a il-6
WO2016159213A1 (ja)	2015-04-01	2016-10-06	中外製薬株式会社	ポリペプチド異種多量体の製造方法
JP7096667B2 (ja)	2015-07-01	2022-07-06	中外製薬株式会社	Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
US12168061B2 (en) *	2015-08-03	2024-12-17	Crage Medical Co., Limited	Antibody against glypican-3 and application thereof
KR101796688B1 (ko)	2015-10-29	2017-12-01	재단법인 목암생명과학연구소	신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
LT3373968T (lt)	2015-11-09	2024-07-10	The Children's Hospital Of Philadelphia	Glipikanas 2 kaip vėžio žymuo ir terapinis taikinys
EP3394098A4 (en)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
BR112018009312A8 (pt)	2015-12-28	2019-02-26	Chugai Pharmaceutical Co Ltd	método para promover eficiência de purificação de polipeptídeo contendo região de fc
US11072666B2 (en)	2016-03-14	2021-07-27	Chugai Seiyaku Kabushiki Kaisha	Cell injury inducing therapeutic drug for use in cancer therapy
EP3430054B1 (en) *	2016-03-15	2021-12-29	Chugai Seiyaku Kabushiki Kaisha	Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
SG11201807765PA (en)	2016-04-28	2018-10-30	Chugai Pharmaceutical Co Ltd	Antibody-containing preparation
CN109689099B (zh)	2016-08-05	2023-02-28	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
JP7125347B2 (ja)	2016-08-22	2022-08-24	中外製薬株式会社	ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
KR20230073346A (ko)	2016-11-28	2023-05-25	추가이 세이야쿠 가부시키가이샤	리간드 결합 활성을 조정 가능한 리간드 결합 분자
JP7185884B2 (ja)	2017-05-02	2022-12-08	国立研究開発法人国立精神・神経医療研究センター	Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US20200216542A1 (en)	2017-09-20	2020-07-09	Chugai Seiyaku Kabushiki Kaisha	Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
CR20240273A (es)	2017-11-01	2024-08-27	Chugai Pharmaceutical Co Ltd	Variantes e isoformas de anticuerpos con actividad biológica reducida (divisional 2020-229)
MX2020005160A (es)	2017-11-28	2020-08-20	Chugai Pharmaceutical Co Ltd	Molecula de union a ligando que tiene actividad de union a ligando ajustable.
AR114112A1 (es)	2018-02-15	2020-07-22	Seattle Genetics Inc	Anticuerpos de glipicano 3 y conjugados de los mismos
WO2019230868A1 (ja)	2018-05-30	2019-12-05	中外製薬株式会社	単ドメイン抗体含有リガンド結合分子
WO2019246563A1 (en)	2018-06-22	2019-12-26	Kite Pharma, Inc.	Chimeric transmembrane proteins and uses thereof
SG11202103234RA (en)	2018-10-01	2021-04-29	Adicet Bio Inc	COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS
WO2020086758A1 (en)	2018-10-23	2020-04-30	Dragonfly Therapeutics, Inc.	Heterodimeric fc-fused proteins
CN121159688A (zh)	2019-03-19	2025-12-19	中外制药株式会社	包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
BR112021023735A2 (pt)	2019-06-05	2022-01-04	Chugai Pharmaceutical Co Ltd	Molécula de ligação de sítio de clivagem de anti-corpo
WO2020246567A1 (ja)	2019-06-05	2020-12-10	中外製薬株式会社	プロテアーゼ基質、及びプロテアーゼ切断配列を含むポリペプチド
US12109235B2 (en)	2019-06-21	2024-10-08	Kite Pharma, Inc.	TGF-beta receptors and methods of use
AU2021260960A1 (en)	2020-04-22	2022-11-24	Dragonfly Therapeutics, Inc.	Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
IL300225A (en)	2020-07-31	2023-03-01	Chugai Pharmaceutical Co Ltd	A pharmaceutical composition including chimeric receptor expressing cells
JP2024537323A (ja) *	2021-10-15	2024-10-10	コンセプトトゥーメディシンバイオテックカンパニー，リミテッド	抗グリピカン３抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04228089A (ja)	1990-05-15	1992-08-18	Kanegafuchi Chem Ind Co Ltd	高カルシウム血症治療・予防剤
EP0729976A1 (en) *	1993-11-19	1996-09-04	Chugai Seiyaku Kabushiki Kaisha	Reconstituted human antibody against human medulloblastomatous cell
DE69637481T2 (de)	1995-04-27	2009-04-09	Amgen Fremont Inc.	Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
UA76934C2 (en) *	1996-10-04	2006-10-16	Chugai Pharmaceutical Co Ltd	Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP3587664B2 (ja)	1996-10-04	2004-11-10	中外製薬株式会社	再構成ヒト抗ｈｍ１．２４抗体
JP4228089B2 (ja)	1997-03-11	2009-02-25	株式会社ニコン	過電流検知機構およびそれを用いた電子閃光装置
US7361336B1 (en)	1997-09-18	2008-04-22	Ivan Bergstein	Methods of cancer therapy targeted against a cancer stem line
ATE373712T1 (de) *	1997-10-03	2007-10-15	Chugai Pharmaceutical Co Ltd	Natürlicher menschlicher antikörper
JP3445153B2 (ja)	1998-06-04	2003-09-08	富士通株式会社	電話番号一時的使用装置及び方法
TWI290832B (en) *	1999-08-23	2007-12-11	Chugai Pharmaceutical Co Ltd	Expression enhancer for HM1.24 antigen
CA2451493C (en) *	2001-06-22	2016-08-23	Chugai Seiyaku Kabushiki Kaisha	Cell growth inhibitors containing anti-glypican 3 antibody

2002
- 2002-06-21 CA CA2451493A patent/CA2451493C/en not_active Expired - Lifetime
- 2002-06-21 PT PT02741243T patent/PT1411118E/pt unknown
- 2002-06-21 DE DE60237929T patent/DE60237929D1/de not_active Expired - Lifetime
- 2002-06-21 KR KR1020037016776A patent/KR100877176B1/ko not_active Expired - Lifetime
- 2002-06-21 EP EP10003378A patent/EP2208784B1/en not_active Expired - Lifetime
- 2002-06-21 EP EP02741243A patent/EP1411118B1/en not_active Expired - Lifetime
- 2002-06-21 JP JP2003507268A patent/JP4281869B2/ja not_active Expired - Lifetime
- 2002-06-21 ES ES02741243T patent/ES2312586T3/es not_active Expired - Lifetime
- 2002-06-21 EP EP07002896A patent/EP1780273B1/en not_active Expired - Lifetime
- 2002-06-21 US US10/481,524 patent/US20040236080A1/en not_active Abandoned
- 2002-06-21 PT PT100033786T patent/PT2208784E/pt unknown
- 2002-06-21 AU AU2002315857A patent/AU2002315857B2/en not_active Expired
- 2002-06-21 DK DK10003378.6T patent/DK2208784T3/da active
- 2002-06-21 ES ES07002896T patent/ES2353335T3/es not_active Expired - Lifetime
- 2002-06-21 WO PCT/JP2002/006237 patent/WO2003000883A1/ja not_active Ceased
- 2002-06-21 AT AT02741243T patent/ATE407204T1/de active
- 2002-06-21 ES ES10003378T patent/ES2399028T3/es not_active Expired - Lifetime
- 2002-06-21 DE DE60228721T patent/DE60228721D1/de not_active Expired - Lifetime
- 2002-06-21 KR KR1020097019979A patent/KR100953520B1/ko not_active Expired - Lifetime
- 2002-06-21 KR KR1020087019090A patent/KR20080077295A/ko not_active Ceased
- 2002-06-21 AT AT07002896T patent/ATE483801T1/de not_active IP Right Cessation
- 2002-06-21 CN CN2007100960379A patent/CN101240022B/zh not_active Expired - Lifetime
- 2002-06-21 CN CNB028125703A patent/CN1314803C/zh not_active Expired - Lifetime
- 2002-06-21 DK DK02741243T patent/DK1411118T3/da active
2005
- 2005-04-28 JP JP2005133154A patent/JP2005225892A/ja not_active Withdrawn
2006
- 2006-11-06 JP JP2006300276A patent/JP2007051159A/ja not_active Withdrawn
2007
- 2007-02-05 US US11/702,780 patent/US7744880B2/en not_active Expired - Lifetime
- 2007-03-22 AU AU2007201255A patent/AU2007201255B2/en not_active Expired
- 2007-06-25 JP JP2007165739A patent/JP2007238632A/ja active Pending
2008
- 2008-02-08 JP JP2008028527A patent/JP2008120828A/ja active Pending
- 2008-09-05 JP JP2008228128A patent/JP4347402B2/ja not_active Expired - Lifetime
2009
- 2009-04-24 JP JP2009105835A patent/JP5596935B2/ja not_active Expired - Lifetime
2010
- 2010-04-26 US US12/799,491 patent/US8263077B2/en not_active Expired - Fee Related
2013
- 2013-03-29 CY CY20131100264T patent/CY1113854T1/el unknown

Also Published As

Publication number	Publication date
ATE407204T1 (de)	2008-09-15
JP4347402B2 (ja)	2009-10-21
KR100953520B1 (ko)	2010-04-21
KR20040030699A (ko)	2004-04-09
US20070172488A1 (en)	2007-07-26
PT2208784E (pt)	2013-04-03
AU2007201255B2 (en)	2010-03-11
ES2312586T3 (es)	2009-03-01
HK1079547A1 (en)	2006-04-07
JP2007051159A (ja)	2007-03-01
JP4281869B2 (ja)	2009-06-17
EP1780273B1 (en)	2010-10-06
CA2451493A1 (en)	2003-01-03
CN1688692A (zh)	2005-10-26
ES2399028T3 (es)	2013-03-25
JP2007238632A (ja)	2007-09-20
CY1113854T1 (el)	2016-07-27
EP2208784B1 (en)	2013-01-02
JP2009024020A (ja)	2009-02-05
WO2003000883A1 (fr)	2003-01-03
CN101240022A (zh)	2008-08-13
EP1411118A1 (en)	2004-04-21
US8263077B2 (en)	2012-09-11
KR100877176B1 (ko)	2009-01-07
ES2353335T3 (es)	2011-03-01
HK1120522A1 (en)	2009-04-03
JP2009161565A (ja)	2009-07-23
US20110002922A1 (en)	2011-01-06
DK1411118T3 (da)	2008-11-17
EP1411118B1 (en)	2008-09-03
KR20080077295A (ko)	2008-08-21
AU2002315857B2 (en)	2007-07-26
CN1314803C (zh)	2007-05-09
CN101240022B (zh)	2012-07-18
CA2451493C (en)	2016-08-23
EP1411118A4 (en)	2005-01-26
KR20090107091A (ko)	2009-10-12
ATE483801T1 (de)	2010-10-15
EP1780273A1 (en)	2007-05-02
DK2208784T3 (da)	2013-03-18
US20040236080A1 (en)	2004-11-25
US7744880B2 (en)	2010-06-29
DE60237929D1 (de)	2010-11-18
JP5596935B2 (ja)	2014-09-24
JP2008120828A (ja)	2008-05-29
JPWO2003000883A1 (ja)	2004-10-07
DE60228721D1 (en)	2008-10-16
AU2007201255A1 (en)	2007-04-19
JP2005225892A (ja)	2005-08-25
EP2208784A1 (en)	2010-07-21

Publication	Publication Date	Title
PT1411118E (pt)	2008-12-09	Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3
GB0209891D0 (en)	2002-06-05	Novel compounds
DK1242401T3 (da)	2007-05-07	Cytotoksiske midler, der omfatter taxaner, og den terapeutiske anvendelse deraf
TW200505890A (en)	2005-02-16	Breast cancer-resistant protein inhibitor
BRPI0317696B8 (pt)	2021-05-25	composição para branqueamento
DE60035032D1 (de)	2007-07-12	Verwendung von pioglitazone zur verbesserung der ketose und der azidose
DE60207198D1 (de)	2005-12-15	Transplantate für die wiederherstellung von osteochondralen schäden
MXPA02006826A (es)	2004-04-05	Un inhibidor de division celular y un metodo de produccion del mismo.
AU2003280918A1 (en)	2004-07-29	Rabbit skin comprising biological active substance and its use
BR0014758A (pt)	2002-07-02	Sistemas e métodos para expressão de proteìna com alto rendimento
SE9802937D0 (sv)	1998-09-01	Novel compounds
DE50310323D1 (de)	2008-09-25	Wässrige polyurethanzubereitungen
WO2004003152A3 (en)	2004-04-08	Sos1 inhibitors
NZ509051A (en)	2003-01-31	Chemotaxis-inhibiting protein of staphylococcus (CHIPS) and its use
MY127675A (en)	2006-12-29	Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
DK1368022T3 (da)	2007-10-01	Anvendelse af en flaske indeholdende en oxaliplatinoplösning
DE60011677D1 (en)	2004-07-22	Tryptase-inhibitoren
WO2003062197A3 (en)	2005-02-10	Nek2 inhibitors
MXPA04005226A (es)	2004-10-11	1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion.
GB0123098D0 (en)	2001-11-14	Use of aminoglycoside resistance gene
ATE506960T1 (de)	2011-05-15	Medikament und verwendung zur tumortherapie
ES2188597T3 (es)	2003-07-01	Uso de una secuencia genica promotora para el tratamiento de enfermedades reumaticas.
AU7398701A (en)	2001-11-20	Cosmetic skin care compositions containing pulegone
AP2000001907A0 (en)	2000-09-30	Crystalline form of paroxetine.
ATE382363T1 (de)	2008-01-15	Pharmazeutische zusammensetzung enthaltend bulbophyllum